



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2014**



<b>Version 6.0 November 21, 2014</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	Throughout document	The ISBT 128 Product Description Code database has been restructured and the version number has been changed to 6.0.0 to reflect this change. The ISBT 128 Standard Terminology for Blood, Cellular Therapy, and Tissue Product Descriptions supports this database and therefore has been given the same version number, 6.0.0.	Requested by ICCBBA to support growth of the ISBT 128 Standard.
2	2.3.2.2.1	Added New Attribute Variables: <ul style="list-style-type: none"><li>• For mnf: noninjectable- converted</li><li>• For mnf: injectable- source</li><li>• For mnf:noninjectable- source</li></ul>	Requested by the US
3	3.2.1.1	Added New Storage Condition: <ul style="list-style-type: none"><li>• ≤37 C</li></ul>	Requested by the US
4	4.1.2	Added New Class: <ul style="list-style-type: none"><li>• CORTICAL BONE BLOCKS</li></ul>	Requested by the US
5	10.2	Added New Attribute Group: <ul style="list-style-type: none"><li>• Storage State</li></ul>	Requested by the US
6	10.2.1.1	Added New Attribute Variables: <ul style="list-style-type: none"><li>• No information provided</li><li>• Frozen</li></ul>	Requested by the US

<b>Version 5.4 October 20, 2014</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	Throughout document	Updated main section titles to more closely reflect the names of the families of products supported by ISBT 128.	For consistency
2	5.1	Added New Class: <ul style="list-style-type: none"><li>• POSTERIOR PART</li></ul>	Requested by the US



3	13.2.1	Removed Retired Class: <ul style="list-style-type: none"> <li>T CELLS, APHERESIS</li> </ul>	Initially retired in version 3.13 and unretired in version 4.26 with the implementation of New Cellular Therapy terminology.
---	--------	---	--

Version 5.3 September 2, 2014			
	Section	Change	Rationale
1	3.2.2.2.2	Updated the definition of the following attribute variable: <ul style="list-style-type: none"> <li>Filtered</li> </ul>	For Clarification
2	3.2.2.2.3	Updated the definitions of the following attribute variables: <ul style="list-style-type: none"> <li>NS HES + NS DMSO</li> <li>NS HES + 5% DMSO</li> <li>NS HES + 10% DMSO</li> </ul>	For Clarification
3	4.1.2	Added New Tissues Class: <ul style="list-style-type: none"> <li>ELBOW</li> <li>FEMUR</li> </ul>	Requested by the US
4	4.3.2.2.5	Added New Attribute Variables: <ul style="list-style-type: none"> <li>Antibiotic solution</li> <li>Vitrification solution</li> </ul>	Requested by the ETTAG-NATTAG Cardiovascular working group
5	8.2.1	Added New Attribute Groups: <ul style="list-style-type: none"> <li>Milk Type</li> <li>Pooling Status</li> <li>Preparation</li> <li>Nutritional Additives</li> <li>Dietary characteristics</li> <li>Calorie Count</li> <li>Nutritional Analysis</li> <li>Donor Classification</li> </ul>	Requested by MBTAG
6	8.2.1.1	Added New Attribute Variables: <ul style="list-style-type: none"> <li>0 to 4C</li> <li>Freeze dried</li> <li>Thawed</li> </ul>	Requested by MBTAG



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2014**



7	8.2.1.3	Added New Attribute Variable: • Not for clinical use	Requested by MBTAG
8	8.2.1.5	Added New Attribute Variable: • Specified recipient	Requested by MBTAG
9	8.2.1.6	Added New Attribute Variables: • Colostrum • Pre-term • Term	Requested by MBTAG
10	8.2.1.7	Added New Attribute Variables: • Pooled, <7 donors • Pooled, donors ≥7 • Pooled, single donor • Single donor expression	Requested by MBTAG
11	8.2.1.8	Added New Attribute Variable: • Fat reduced	Requested by MBTAG
12	8.2.1.9	Added New Attribute Variable: • Nutrients added	Requested by MBTAG
13	8.2.1.10	Added New Attribute Variable: • Special dietary characteristics	Requested by MBTAG
14	8.2.1.11	Added New Attribute Variable: • Calorie value specified	Requested by MBTAG
15	8.2.1.12	Added New Attribute Variable: • Nutritional analysis specified	Requested by MBTAG
16	8.2.1.13	Added New Attribute Variables: • Volunteer donor • Paid donor	Requested by MBTAG
17	9.2	Added Attribute Groups and Variables applicable to Other Therapies category.	For completeness
18	13	Changed section name from Retired Codes to Retired Terminology.	For clarification
19	13	Changed instances of 'codes' to 'terminology' throughout the section.	For clarification



Version 5.2 August 1, 2014			
	Section	Change	Rationale
1	1	Added reference to In Vivo Diagnostic MPHO in the last paragraph of the Introduction section.	For Completeness
2	3.2.2.2.5	Added a note to the definition of the attribute Concurrent Plasma.	Requested by CTCLAG  The Class CONCURRENT PLASMA, APHERESIS specifies that this product only applies to apheresis collections. Therefore, this also applies to the attribute.
3	6.3	Added a note to the Attributes section stating that Plasma Derivatives and In Vivo Diagnostic MPHO (Medical Products of Human Origin) are in the Other Blood Products category. They therefore share attribute groups and variables; not all variables are applicable.	For Clarification
4	6.3.1.1	Added Core Conditions applicable to the Other Blood Products category.	For Completeness
5	6.3.2.1	Added Groups applicable to the Other Blood Products category.	For Completeness
6	6.3.2.2.2	Added variables for Altered group applicable to Other Blood Products category.	For Completeness
7	6.3.2.2.3	Added variables for Donor-Intended Recipient Relationship group applicable to Other Blood Products category.	For Completeness
8	7	Added New Section for In Vivo Diagnostic MPHO.	Requested by The Netherlands



9	7.1	Added New In Vivo Diagnostic MPHO Classes: <ul style="list-style-type: none"> <li>• RADIOLABELED DIAGNOSTICS, LEUKOCYTES</li> <li>• RADIOLABELED DIAGNOSTICS, PLATELETS</li> <li>• RADIOLABELED DIAGNOSTICS, RED BLOOD CELLS</li> </ul>	Requested by The Netherlands
10	7.2.1	Added Modifier applicable to Other Blood Products category.	For Completeness
11	7.3.1.1	Added New Core Conditions Variables: <ul style="list-style-type: none"> <li>• ACD-A</li> <li>• ACD-A-HES</li> <li>• Heparin-HES</li> </ul>	Requested by The Netherlands
12	7.3.2.1	Added Attribute Groups: <ul style="list-style-type: none"> <li>• Altered</li> <li>• Donor-Intended Recipient Relationship</li> </ul>	Requested by The Netherlands
13	7.3.2.2.1	Added Blood Group Variables applicable to Other Blood Products category.	For Completeness
14	7.3.2.2.2	Added Attribute Variables: <ul style="list-style-type: none"> <li>• Not specified</li> <li>• Heat denatured</li> </ul>	Requested by The Netherlands
15	7.3.2.2.3	Added Attribute Variables: <ul style="list-style-type: none"> <li>• Not specified</li> <li>• Autologous</li> </ul>	Requested by The Netherlands
16	8 to 13	Renumbered sections downstream of section 7.	Due to addition of In Vivo Diagnostic MPHO Terminology in section 7



Version 5.1 July 3, 2014			
	Section	Change	Rationale
1	2.3.2.2.7	New Attribute Added to Preparation- Additional Information Group: <ul style="list-style-type: none"> <li>Multiple wash cycles</li> </ul>	Requested by Canada
2	3.1.3	Added New Abbreviations; <ul style="list-style-type: none"> <li>CP(A) - CONCURRENT PLASMA, APHERESIS</li> <li>MNC(UCT) - MNC, UMBILICAL CORD TISSUE</li> </ul>	Requested by CTCLAG
3	6.3.1.1	New Storage Condition Added: <ul style="list-style-type: none"> <li>rt</li> </ul>	Requested by the US

Version 5.0 June 6, 2014			
	Section	Change	Rationale
1	3.2.2.2.3	New Attribute Added to Cryoprotectant Group: <ul style="list-style-type: none"> <li>(NS HES + NS DMSO)</li> </ul>	Requested by Belgium
2	7.2.1	<ul style="list-style-type: none"> <li>Changed <math>\leq -80</math> C to <math>\leq -70</math> C</li> </ul>	MBTAG decided $\leq -70$ C was more realistic if target temperature was $\leq -80$ C. No Product Description Codes using $\leq -80$ C have been used as of 06 Jun 2014.

Version 4.34 April 24, 2014			
	Section	Change	Rationale
1	2.3.2.2.12	New Attribute Added to Hematocrit Group: <ul style="list-style-type: none"> <li>0.50 – 0.55</li> </ul>	Requested by Ireland



2	4.1.1	<p>Changed the ISBT 128 Database name for the class:</p> <ul style="list-style-type: none"> <li>VALVE, PULMONARY, W MAIN, L/R ARTERIES</li> </ul>	Removed 2 spaces to accommodate the 36 character field size of the Class field in the Class table within the ISBT 128 Product Description Code Database.
---	-------	---	--

Version 4.33 March 18, 2014			
	Section	Change	Rationale
1	2.3.1	Updated PAS table to include 'T-PAS+' as an alternative name for PAS-E	Requested by the US
2	2.3.2.2.5	<p>New Attribute Added:</p> <ul style="list-style-type: none"> <li>Plasma removed and SAGM added</li> </ul>	Requested by Ireland
3	2.3.2.2.5	'Red Blood Cells reduced by sedimentation' was changed to 'RBC content reduced'	Requested by Ireland
4	3.1.2	<p>New Classes Added:</p> <ul style="list-style-type: none"> <li>MSC, PLACENTA</li> <li>MSC, UMBILICAL CORD</li> </ul>	Requested by China
5	3.2.2.2.12	<p>New Attribute Added:</p> <ul style="list-style-type: none"> <li>Viral specific T cell enriched</li> </ul>	<p>Requested by Singapore</p> <p>Inadvertently omitted in version 4.28</p>
6	4.1.1	<p>Renamed the Following Classes and updated the definitions:</p> <ul style="list-style-type: none"> <li>ABDOMINAL BIFURCATION to AORTOILIAC, CONDUIT</li> <li>AORTIC ARCH to AORTA, ARCH</li> <li>COMMON ILIAC ARTERY to ARTERY, COMMON ILIAC</li> <li>FEMORAL ARTERY to ARTERY, FEMORAL, COMMON</li> </ul>	Requested by the ETTAG-NATTAG Cardiovascular terminology working group



		<ul style="list-style-type: none"> <li>• PULMONARY PATCH to PULMONARY, MAIN ARTERY PATCH</li> <li>• SUPERFICIAL FEMORAL ARTERY to ARTERY, FEMORAL, SUPERFICIAL</li> <li>• THORACIC AORTA to AORTA, DESCENDING, THORACIC</li> <li>• VENA CAVA INFERIOR to VEIN, INFERIOR VENA CAVA</li> </ul>	
7	4.1.1	<p>New Classes Added:</p> <ul style="list-style-type: none"> <li>• AORTA, ARCH, WITH DESCENDING THORACIC</li> <li>• AORTA, ASCENDING</li> <li>• AORTA, ASCENDING, WITH ARCH</li> <li>• AORTA, DESCENDING, ABDOMINAL</li> <li>• AORTOILIAC, CONDUIT</li> <li>• VALVE, AORTIC, WITH ASCENDING AORTA</li> <li>• VALVE, AORTIC, WITH ASCENDING AORTA AND ARCH</li> <li>• VALVE, AORTIC, WITH ASCENDING AORTA AND PARTIAL ARCH</li> <li>• ARTERY, BRACHIAL</li> <li>• ARTERY, INTERNAL THORACIC</li> <li>• ARTERY, RADIAL</li> <li>• ARTERY, ULNAR</li> <li>• HEART, PARTIAL, WITH VALVES</li> <li>• HEART, PARTIAL, WITHOUT VALVES</li> <li>• HEART, WITH PERICARDIUM</li> <li>• VALVE, MITRAL, PATCH</li> <li>• PULMONARY, MAIN AND LEFT ARTERIES</li> <li>• PULMONARY, MAIN ARTERY WITH LEFT AND RIGHT ARTERIES</li> </ul>	Requested by the ETTAG-NATTAG Cardiovascular terminology working group





		<ul style="list-style-type: none"> <li>• PULMONARY, MAIN ARTERY</li> <li>• PULMONARY, MAIN ARTERY PATCH</li> <li>• PULMONARY, MAIN AND RIGHT ARTERIES</li> <li>• VALVE, PULMONARY, MONOCUSP</li> <li>• VALVE, PULMONARY, ONE LEAFLET</li> <li>• VALVE, PULMONARY, TWO LEAFLETS</li> <li>• VALVE, PULMONARY, WITH MAIN ARTERY</li> <li>• VALVE, PULMONARY, WITH MAIN, LEFT AND RIGHT ARTERIES</li> <li>• VALVE, PULMONARY, WITH MAIN, LEFT ARTERY</li> <li>• VALVE, PULMONARY, WITH MAIN, RIGHT ARTERY</li> <li>• VEIN, FEMORAL</li> <li>• VEIN, GREAT SAPHENOUS</li> <li>• VEIN, SMALL SAPHENOUS</li> </ul>	
8	4.1.4	<p>Moved Classes:</p> <ul style="list-style-type: none"> <li>• Pericardial Patch</li> <li>• Pericardium</li> </ul>	ETTAG-NATTAG Cardiovascular terminology working group determined that these terms will be handled as membrane terminology
9	6.3.2.2.1	<p>Added New Blood Group Attribute:</p> <ul style="list-style-type: none"> <li>• ABO independent</li> </ul>	Requested by Ireland
10	7.2.1	<p>Added New Storage Condition:</p> <ul style="list-style-type: none"> <li>• ≤-80 C</li> </ul>	Requested by Spain
11	12.3.1	<p>Retired Tissue Terminology:</p> <ul style="list-style-type: none"> <li>• AORTIC NON-VALVED CONDUIT</li> <li>• AORTIC PATCH</li> <li>• BLOOD VESSEL</li> <li>• SAPHENOUS VEIN</li> </ul>	Terminology retired by the ETTAG-NATTAG Cardiovascular terminology working group



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2014**



<b>Version 4.32 February 6, 2014</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	3.1.2	Updated definition of Concurrent Plasma.	Requested by CTCLAG
2	3.2.2.2.1	New Attribute Added: <ul style="list-style-type: none"> <li>For use in further processing donor's cell product</li> </ul>	Requested by CTCLAG

<b>Version 4.31 January 13, 2014</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	2.3.2.2.5	New Attribute Added: <ul style="list-style-type: none"> <li>Saline added</li> </ul>	Requested by the US
2	4.1.4	New Class Added: <ul style="list-style-type: none"> <li>Peripheral Nerve</li> </ul>	Requested by the US



Version 4.30 December 30, 2013			
	Section	Change	Rationale
1	3.2.1	In section (1) all reference to additives were removed.	Per request of CTCLAG, additives are not encoded in the core conditions for Cellular Therapy products.
2	3.2.2.1	The definition of the Preparation – Other Additive group was broadened to describe all additives present in the products.	Cellular therapy products encode all additive information in this group.
3	3.2.2.2.4 3.2.2.2.5 3.2.2.2.6	Changed the term paperwork to documentation throughout this section.	For consistency
4	4.1.2	Added new Class: • CARTILAGE, JOINT, KNEE	Requested by Denmark
5	4.1.2	Added new Classes: • RADIUS • RADIUS, DISTAL • RADIUS, PROXIMAL • ULNA, DISTAL • ULNA, PROXIMAL	Requested by the UK
6	4.1.4	Added new Classes: • LARYNX WITH TRACHEA • LARYNX AND TRACHEA WITH BIFURCATION	Requested by Austria
7	4.3.2.1	Added new Attribute Group: • Additives	Requested by Austria
8	4.3.2.2.1	Added new Attribute Variables: • Not specified • Additives:Yes	Requested by Austria



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2013**



9	4.3.2.2.1	Added new Attribute Variables: <ul style="list-style-type: none"> <li>• Albumin</li> <li>• Albumin + other</li> <li>• 3rd Party donor plasma</li> <li>• 3rd Party donor plasma + other</li> <li>• Additives:yes incl animal src</li> <li>• Autologous plasma</li> <li>• Autologous plasma + other</li> </ul>	Requested by ETAG
10	7	Moved Classes in the Other Therapies group to new sections. <ul style="list-style-type: none"> <li>• Human Milk</li> <li>• Serum Eye Drops</li> <li>• Fecal Microbiota</li> </ul>	Moved to new sections by ICCBBA to better accommodate users in each area of interest.

Version 4.29 November 26, 2013			
	Section	Change	Rationale
1	3.1.2	Added new Class: <ul style="list-style-type: none"> <li>• MNC, UMBILICAL CORD TISSUE</li> </ul>	Requested by the US
2	3.2.1.1	Added new storage temperature: <ul style="list-style-type: none"> <li>• 10-20 C</li> </ul>	Requested by Singapore
3	4.1.4	Added new Classes: <ul style="list-style-type: none"> <li>• TRACHEA</li> <li>• TRACHEA WITH BIFURCATION</li> <li>• TRACHEA, PART</li> <li>• TRACHEA, PART WITH BIFURCATION</li> </ul>	Requested by Austria
4	5.2	Added new Attribute Group: <ul style="list-style-type: none"> <li>• Transport Solution</li> </ul>	Requested by Croatia
5	5.2.1.8	Added new Attribute Variables: <ul style="list-style-type: none"> <li>• Not specified</li> <li>• Dextran</li> </ul>	Requested by Croatia
6	7.1.3	Added new Class: <ul style="list-style-type: none"> <li>• Fecal Microbiota</li> </ul>	Requested by the US



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2013**



<b>Version 4.28 October 24, 2013</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	2.3.2.2.10	Added new attributes: <ul style="list-style-type: none"> <li>• 11 units</li> <li>• 12 units</li> </ul>	Requested by the US
2	3.2.1.1	Changed Citrate/Heparin to Citrate+Heparin.	Changed to match the ISBT 128 database name.
3	3.2.2.2.13	<ul style="list-style-type: none"> <li>• Changed Alpha Beta T/B cell reduced to Alpha Beta T+B cell reduced.</li> <li>• Changed T/B cell reduced to T+B cell reduced.</li> </ul>	Changed to match the ISBT 128 database name.
4	4.3.2.1	Added new Attribute Group: <ul style="list-style-type: none"> <li>• Additional Processing</li> </ul>	Requested by the UK
5	4.3.2.2	Sub sections renumbered due to addition of new Attribute Group.	For consistency
6	4.3.2.2.1	Added new Attribute Variables: <ul style="list-style-type: none"> <li>• Not specified</li> <li>• Marrow depleted</li> <li>• Cleaned</li> </ul>	Requested by the United Kingdom  Requested by Advisory Group

<b>Version 4.27 September 17, 2013</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	2.3.1.1	Added new third position value: <ul style="list-style-type: none"> <li>• &lt;-80C</li> </ul>	Added for Completeness
2	2.3.2.2.5	Added new Attribute Variable: <ul style="list-style-type: none"> <li>• Plasma reduced/Saline added</li> </ul>	Requested by the US
3	3.1.2	Added new Class: <ul style="list-style-type: none"> <li>• NC, SYNOVIAL FLUID</li> </ul>	Requested by the US



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2013**



4	3.2.1	Added the sentence, "Other volume information may be given as additional label text."	This will allow users to print total volume (including anticoagulant) on the label instead of nominal collection volume.
---	-------	---	--

<b>Version 4.26 August 15, 2013</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	3.1.1	Redefined Subcategory 1 class types for cellular therapy.	The Subcategory 1 class name format was revised to describe the composition of the cellular therapy product and will no longer describe the intended purpose of the collection.
2	3.1.1	Redefined Subcategory 2 class types for cellular therapy.	The revised Subcategory 2 class names no longer utilize a hyphen and the use of "TC" (Therapeutic Cell) is no longer used.
3	3.1.2	Renamed the following classes: <ul style="list-style-type: none"> <li>• NC, ADIPOSE CELLS to NC, ADIPOSE TISSUE</li> <li>• NC-MSC ATD to MSC, ADIPOSE TISSUE</li> <li>• NC-MSC DPD to MSC, DENTAL PULP</li> <li>• NC-MSC WJD to MSC, WHARTON'S JELLY</li> <li>• NC, TUMOR CELLS to MALIGNANT CELLS, TUMOR</li> <li>• TC, APHERESIS to MNC, APHERESIS</li> <li>• TC-BLINDED STUDY to INVESTIGATIONAL PRODUCT</li> </ul>	The revised class names follow the format of listing the cell type followed by the source. The use of "TC" (Therapeutic Cell) is no longer used.



		<ul style="list-style-type: none"> <li>• TC, CORD BLOOD to NC, CORD BLOOD</li> <li>• TC, MARROW to NC, MARROW</li> <li>• TC, MSC MD to MSC, MARROW</li> <li>• TC, WHOLE BLOOD to NC, WHOLE BLOOD</li> </ul>	
4	3.1.2	Renamed the class name from TC, PANCREATIC ISLETS to PANCREATIC ISLETS	The use of TC (Therapeutic Cell) is no longer used. This class is an exception that will not follow the cell therapy format of Cell Type, Source. PANCREATIC ISLETS will become a tissue class name in the future.
5	3.1.2	<p>Added the following classes:</p> <ul style="list-style-type: none"> <li>• DC, APHERESIS</li> <li>• DC, CORD BLOOD</li> <li>• DC, MARROW</li> <li>• DC, WHOLE BLOOD</li> <li>• MALIGNANT CELLS, APHERESIS</li> <li>• MALIGNANT CELLS, MARROW</li> <li>• MALIGNANT CELLS, WHOLE BLOOD</li> <li>• MSC, CORD BLOOD</li> <li>• NK CELLS, APHERESIS</li> <li>• NK CELLS, CORD BLOOD</li> <li>• NK CELLS, MARROW</li> <li>• NK CELLS, WHOLE BLOOD</li> <li>• T CELLS, APHERESIS</li> <li>• T CELLS, CORD BLOOD</li> <li>• T CELLS, MARROW</li> <li>• T CELLS, TUMOR</li> <li>• T CELLS, WHOLE BLOOD</li> </ul>	Requested by CTCLAG under the new cellular therapy terminology.
6	3.1.2	Revised the definitions for most cellular therapy class names.	To follow a consistent format with the revised terminology.
7	3.1.3	Expanded table of abbreviations for cellular therapy class names.	To standardize the use of abbreviations.



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2013**



8	3.2.2.1	Added the following attribute groups: <ul style="list-style-type: none"> <li>• Modification</li> <li>• Mobilization</li> <li>• Pooled Single Donor</li> <li>• Cultured</li> <li>• Enrichment</li> <li>• Reduction</li> </ul>	Requested by CTCLAG
9	3.2.2.2.2	Added new attributes: <ul style="list-style-type: none"> <li>• Electroporated</li> <li>• Lysate</li> <li>• Pulsed</li> </ul>	Requested by CTCLAG
10	3.2.2.2.5	Added new attributes: <ul style="list-style-type: none"> <li>• Concurrent plasma</li> <li>• Concurrent plasma + other</li> </ul>	Requested by CTCLAG
11	3.2.2.2.8	Added new Modification attribute group and variables.	Requested by CTCLAG to replace the use of Modifiers in cellular therapy product descriptions.
12	3.2.2.2.9	Added new Mobilized attribute group and variables.	Requested by CTCLAG. Mobilization is no longer addressed in the definitions of relevant class names and is no longer used as a modifier.
13	3.2.2.2.10	Added new Pooled Single Donor attribute group and variables.	Requested by CTCLAG to replace the use of the Pooled Single Donor modifier.
14	3.2.2.2.11	Removed the Cultured attribute from the Manipulation attribute group and created a new Cultured attribute group and variables.	Requested by CTCLAG





15	3.2.2.2.12	<p>Relocated the following attributes from the Manipulation attribute group to a new Manipulation Enrichment attribute group:</p> <ul style="list-style-type: none"> <li>• Buffy coat enriched</li> <li>• CD4 enriched</li> <li>• CD34 enriched</li> <li>• CD56 enriched</li> <li>• CD133 enriched</li> <li>• Mononuclear cell enriched</li> <li>• Monocyte enriched</li> </ul>	To separate the various types of manipulations and allow for better categorization of attributes.
16	3.2.2.2.12	<p>Added the following attributes to the new Manipulation Enrichment attribute group:</p> <ul style="list-style-type: none"> <li>• T Reg enriched</li> <li>• CTL enriched</li> <li>• TIL enriched</li> </ul>	Requested by CTCLAG to replace the use of these terms as part of the class name.
17	3.2.2.2.13	<p>Relocated the following attributes from the Manipulation attribute group to a new Manipulation Reduction attribute group:</p> <ul style="list-style-type: none"> <li>• Alpha Beta T cell reduced</li> <li>• Alpha Beta T/B cell reduced</li> <li>• B cell reduced</li> <li>• CD8 reduced</li> <li>• Plasma reduced</li> <li>• RBC reduced</li> <li>• T/B cell reduced</li> <li>• T cell reduced</li> <li>• Tumor cells reduced</li> </ul>	To separate the various types of manipulations and allow for better categorization of attributes.
18	10.2.1	<p>Added the following cellular therapy class names to the list of retired terms:</p> <ul style="list-style-type: none"> <li>• TC-APC</li> <li>• TC-CTL</li> <li>• TC-DC</li> <li>• TC-INV</li> <li>• TC-MSC</li> <li>• TC-NK CELLS</li> <li>• TC-T CELLS</li> <li>• TC-TIL</li> <li>• TC-T REG CELLS</li> <li>• TC, TUMOR DERIVED</li> </ul>	Requested by CTCLAG



19	10.2.2	<p>Added the following cellular therapy modifier names to the list of retired terms:</p> <ul style="list-style-type: none"> <li>• Cryopreserved</li> <li>• Cryopreserved Non-Mobilized</li> <li>• Frozen</li> <li>• Mobilized</li> <li>• Non-Mobilized</li> <li>• Pooled, Single Donor</li> <li>• Pooled, Single Donor Cryopreserved</li> <li>• Pooled, Single Donor Thawed Washed</li> <li>• Thawed</li> <li>• Thawed Washed</li> <li>• Thawed Washed Non-Mobilized</li> <li>• Washed</li> </ul>	<p>Requested by CTCLAG. Modifiers will no longer be used in cellular therapy product descriptions.</p>
20	10.2.5.1.4	<p>Added the following cellular therapy attributes to the list of retired Manipulation terms:</p> <ul style="list-style-type: none"> <li>• Alpha Beta T cell reduced</li> <li>• Alpha Beta T/B cell reduced</li> <li>• B cell reduced</li> <li>• buffy coat enriched</li> <li>• CD4 enriched</li> <li>• CD8 enriched</li> <li>• CD34 enriched</li> <li>• CD133 enriched</li> <li>• Cultured</li> <li>• Diluted</li> <li>• Monocyte enriched</li> <li>• Mononuclear cells enriched</li> <li>• Plasma reduced</li> <li>• RBC reduced</li> <li>• T/B cell reduced</li> <li>• T cell reduced</li> <li>• Tumor cells reduced</li> </ul>	<p>These terms were retired from the Manipulation attribute group and were put into a different attribute group.</p>



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2013**



<b>Version 4.25 July 11, 2013</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	3.1.3	Added new Classes: <ul style="list-style-type: none"> <li>• CHONDROCYTES, CARTILAGE</li> <li>• KERATINOCYTES, SKIN</li> <li>• FIBROBLASTS, SKIN</li> </ul>	Requested by Iran
2	3.2.1	Added new Modifier: <ul style="list-style-type: none"> <li>• Pooled, Single Donor Cryopreserved</li> </ul>	Requested by Brazil
3	7.2.1	<ul style="list-style-type: none"> <li>• Added new Storage Condition: &lt;=-20C</li> </ul>	Requested by the UK

<b>Version 4.24 June 12, 2013</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1		No changes made to this document. Version numbering updated to correspond with current Product Description Code Database.	

<b>Version 4.23 May 8, 2013</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	2.3.2.2.10	Added new Attribute Variable: Pediatric dose	Requested by the US
2	3.3.2.2.2	Added new Attribute Variable: αβ T cell reduced	Requested by the Netherlands
3	4.1.2	Added new Class: ULNA	Requested by Canada



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2013**



<b>Version 4.22 April 4, 2013</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1		No changes made to this document. Version numbering updated to correspond with current Product Description Code Database.	

<b>Version 4.21 March 15, 2013</b>			
	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
1	1	Added reference to Organ Terminology in the last paragraph of the Introduction section.	For Completeness
2	3.1.3	Added the sentence, "Mobilized unless otherwise stated in Modifier" to the definition of HPC, APHERESIS.	Inadvertently omitted in version 4.8
3	7.2	Added New Attribute Group: Additives	Requested by Austria
4	7.2.1	Added New Attribute Variables: <ul style="list-style-type: none"> <li>• 20-24C</li> <li>• &lt;=-18C</li> </ul>	Requested by Austria
5	7.2.4	Added New Attribute Group: Additives Group Added Attribute Variable: <ul style="list-style-type: none"> <li>• Saline</li> </ul>	Requested by Austria
6	7.2.5	Added Attribute Variables: <ul style="list-style-type: none"> <li>• Allogeneic</li> <li>• Autologous</li> </ul>	Requested by Austria
7	9	Added New Section for Organs	Requested by Austria



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2013**



8	9.1	<p>Added New Organ Classes:</p> <ul style="list-style-type: none"> <li>• HEART</li> <li>• HEART LUNG</li> <li>• INTESTINE</li> <li>• KIDNEY, EN BLOC</li> <li>• KIDNEY, SINGLE</li> <li>• LIVER, SPLIT</li> <li>• LIVER, SPLIT, LEFT</li> <li>• LIVER, SPLIT, RIGHT</li> <li>• LUNG, DOUBLE</li> <li>• LUNG, LEFT</li> <li>• LUNG, RIGHT</li> <li>• MULTIVISCERAL</li> <li>• PANCREAS</li> <li>• RECONSTRUCTION TISSUE</li> <li>• VESSELS FOR RECONSTRUCTION</li> <li>• WHOLE LIVER</li> </ul>	Requested by UNOS
9	9.2	<p>Added New Attributes Groups:</p> <ul style="list-style-type: none"> <li>• Anatomical Position</li> <li>• Donor Type</li> <li>• Intended Use</li> <li>• Vessels</li> </ul>	Requested by UNOS
10	9.2.1	<p>Added Attribute Variables:</p> <ul style="list-style-type: none"> <li>• Not specified</li> <li>• Left</li> <li>• Right</li> </ul>	Requested by UNOS
11	9.2.2	<p>Added Attribute Variables:</p> <ul style="list-style-type: none"> <li>• Deceased</li> <li>• Living</li> </ul>	Requested by UNOS
12	9.2.3	<p>Added Attribute Variables:</p> <ul style="list-style-type: none"> <li>• For transplant</li> <li>• For research only</li> <li>• For cell isolation</li> </ul>	Requested by UNOS
13	9.2.4	<p>Added Attribute Variables:</p> <ul style="list-style-type: none"> <li>• Not Applicable or Not specified</li> <li>• Artery, Iliac</li> <li>• Artery, Pulmonary</li> <li>• Vein, Iliac</li> </ul>	Requested by UNOS
14	10	Renumbered Retired Codes Section	Due to addition of Organ Terminology



Version 4.20 February 5, 2013			
	Section	Change	Rationale
1	3.3.2.1	Added Irradiation group	Requested by the Netherlands
2	3.3.2.2.7	Added Irradiation group and attribute variables	Requested by the Netherlands.
3	7.1	Separated Classes section into categories: <ul style="list-style-type: none"> <li>• Human Milk</li> <li>• Topical Products of Human Origin</li> </ul>	Categories were separated to distinguish the types of products that are not transplanted or transfused.
4	7.1.2	Added new Class - SERUM EYE DROPS	Requested by Austria

Version 4.19 January 21, 2013			
	Section	Change	Rationale
1	1	Added reference to Other Therapies in the last paragraph of the Introduction section.	For Completeness
2	4.1.2	Updated Tendon Terminology. Soft Tissues Classes that specified right/left in the Class name were changed so that left/right are now attributes. These changes resulted in renaming classes as well as updating certain definitions.  <b><i>To view a full list of changes contact the ICCBBA office.</i></b>	Requested by NATTAG



**ISBT 128 Standard Terminology for Blood, Cellular Therapy, and  
Version Control Sheet 2013**



3	4.1.2	<p>Added new Tendon Terminology:</p> <ul style="list-style-type: none"> <li>• TENDON, ACHILLES, WITH SHAPED BONE BLOCK</li> <li>• TENDON, EXTENSOR DIGITORUM LONGUS</li> <li>• TENDON, EXTENSOR HALLUCIS LONGUS</li> <li>• TENDON, PATELLAR WITH PROXIMAL TIBIA</li> <li>• TENDON, PATELLAR WITH WHOLE PATELLA AND TIBIA BONE BLOCK</li> <li>• TENDON, PATELLAR WITH WHOLE TIBIA AND PATELLAR BONE BLOCK</li> <li>• TENDON, PERONEUS BREVIS</li> <li>• TENDON, PERONEUS LONGUS</li> <li>• TENDON, QUADRICEP</li> <li>• TENDON, QUADRICEP WITH SHAPED BONE BLOCK</li> <li>• TENDON, ROTATOR CUFF</li> </ul>	Requested by NATTAG
4	7	Changed name of chapter. Renamed Milk Banking Terminology to Other Therapies.	Made more generic to support broadening the product category to include other products that are not transplanted or transfused.
5	7.2.4	Renamed Milk Banking attribute group: Nutritional Use Status is now Processing Status	Made more generic to support broadening the product category to include other products that are not transplanted or transfused.
6	7.2.5	Added new attribute group, Donor-Intended Recipient Information	Requested by the Austria



7	9.3.1	<p>Retired Tendon Terminology. Soft Tissues Classes that were too general or specified right/left were retired:</p> <ul style="list-style-type: none"><li>• MENISCI, LEFT</li><li>• MENISCI, RIGHT</li><li>• MENISCUS</li><li>• MENISCUS, LATERAL, LEFT</li><li>• MENISCUS, LATERAL, RIGHT</li><li>• MENISCUS, MEDIAL, LEFT</li><li>• MENISCUS, MEDIAL, RIGHT</li><li>• TENDON</li><li>• TENDON, ACHILLES, LEFT</li><li>• TENDON, ACHILLES, RIGHT</li><li>• TENDON, PATELLA, LEFT</li><li>• TENDON, PATELLA, RIGHT</li><li>• TENDON, SEMITENDINOSUS, LEFT</li><li>• TENDON, SEMITENDINOSUS, RIGHT</li><li>• TENDON, TOE EXTENSOR</li></ul> <p><b><i>To view a full list of changes contact the ICCBBA office.</i></b></p>	Requested by NATTAG
---	-------	---	---------------------





## ISBT 128 Standard Terminology for Blood, Cellular Therapy, and Tissue Product Descriptions

### Version Control Sheet 2012

Version 4.18 November 19, 2012			
	Section	Change	Rationale
1		No changes made to this document. Version numbering updated to correspond with current Product Description Code Database.	

Version 4.17 November 16, 2012			
	Section	Change	Rationale
1	1	Added reference to reproductive products in the last paragraph of the Introduction section.	For Completeness
2	4.1.4	Retired tissues class OVARIAN TISSUE	Reclassified as a reproductive product
3	8	Added new section for Reproductive terminology.	Requested by Sweden
4	9	Renumbered Retired Code section	Due to addition of Reproductive Terminology
5	9.2.4.1.4	Removed CD56 enriched	Determined to be a valid attribute
6	9.3.1	Added OVARIAN TISSUE	Reclassified as a reproductive product



Version 4.16 October 19, 2012			
	Section	Change	Rationale
1	1.1	<p>At a minimum a product description will have a component class; modifiers and attributes are added as applicable.</p> <p>The previous wording in this section may have suggested that a class, modifier, and attribute values were required for each product description.</p>	Clarification
2	2.3.1.1	<p>New Core Conditions Added:</p> <ul style="list-style-type: none"> <li>• CPD&gt;PAS-D</li> <li>• ACD-A&gt;PAS-D</li> </ul>	Requested by Austria
3	2.3.2.2.5	<p>New Attributes Added to the Altered Group:</p> <ul style="list-style-type: none"> <li>• Supernatant removed and SD-plasma added</li> <li>• Supernatant removed and Q-plasma added</li> </ul>	Requested by Austria
4	4.1.4	<p>New Tissues Classes Added:</p> <ul style="list-style-type: none"> <li>• UMBILICAL CORD TISSUE</li> <li>• ADIPOSE TISSUE</li> </ul>	Requested by Taiwan

Version 4.15 September 2012			
	Section	Change	Rationale
1	1	Added reference to Milk in the last paragraph of the Introduction section.	For Completeness
2	2.3.2.2.7	<p>Updated definitions for the attribute to the Preparation – Additional Information group:</p> <ul style="list-style-type: none"> <li>• RT&lt;=24h reffg</li> <li>• RT&lt;=24h frozen&lt;=24h</li> </ul>	Definition now applicable to apheresis and whole blood collections.
3	3.3.2.2.2	<p>Added new Attribute to the Manipulation group:</p> <ul style="list-style-type: none"> <li>• CD56 enriched.</li> </ul>	Requested by Singapore



4	4.1.2	Added New Tissue class: TENDON, SEMITENDINOSUS/GRACILIS	Requested by Scotland
5	4.1.4	Added New Tissue class: <ul style="list-style-type: none"> <li>• PLACENTA</li> <li>• PLACENTA WITH UMBILICAL CORD</li> <li>• PLACENTA WITH UMBILICAL CORD AND FETAL MEMBRANES</li> <li>• FETAL MEMBRANES</li> <li>• OVARIAN TISSUE</li> <li>• PARATHYROID GLANDS</li> </ul>	Requested by Austria
6	7	Added new section for Milk Banking terminology.	Requested by Scotland
7	8	Renumbered Retired Code section	Due to addition of Milk Banking Terminology

Version 4.14 August 2012			
	Section	Change	Rationale
1	2.3.1.1	Added definitions for new core conditions: <ul style="list-style-type: none"> <li>• AS7 (Additive Solution 7)</li> <li>• CPD (Citrate Phosphate Dextrose – Additive Solution 7)</li> </ul>	Requested by the US
2	2.3.2.2.7	Added new attribute to the Preparation – Additional Information group: <ul style="list-style-type: none"> <li>• RT&lt;=24h refig</li> <li>• RT&lt;=24h frozen&lt;=24h</li> </ul>	Requested by the US
3	4.1.2	Added new Tissue class FASCIA LATA	Requested by Denmark
4	4.3.2.2.4	Added new attribute to the Type of Preservation group, Solvent dehydrated	Requested by Denmark



Version 4.13 July 2012			
	Section	Change	Rationale
1	1	Add the following statement to the Introduction section of the Standard Terminology document : “All references to biologic materials in this document are of human origin unless specifically stated otherwise.”	For Clarification
2	1	Added reference to ocular tissues in the last paragraph of the Introduction section.	For Completeness
3	2.3.2.1	<ul style="list-style-type: none"> <li>Added new Donor Exposure attribute group.</li> <li>Revised definition of dosage attribute group.</li> </ul>	Proposal 12-003
4	2.3.2.2.10	<ul style="list-style-type: none"> <li>Changed verbiage in Dosage group. Term ‘donors’ changed to ‘units’</li> <li>Note added at the end of the Dosage attribute group section.</li> </ul>	Proposal 11-007
5	2.3.2.2.14	Added the following Donor Exposure attributes: <ul style="list-style-type: none"> <li>Default: No information</li> <li>From multiple donors, number not specified – Pool prepared from multiples donors. The number of donors is not specified.</li> <li>From 2 donors – Pool prepared from products from 2 donors.</li> <li>From 3 donors – Pool prepared from products from 3 donors.</li> <li>From 4 donors – Pool prepared from products from 4 donors.</li> <li>From 5 donors – Pool prepared from products from 5 donors.</li> </ul>	Proposal 12-003
6	3.1.3	Added the following cellular therapy class names: <ul style="list-style-type: none"> <li>NC-MSD ATD</li> <li>NC-MSD DPD</li> <li>NC-MSD WJD</li> </ul>	Requested by Taiwan
7	3.3.2.2.5	Added new variable in the Other Additives attribute group: <ul style="list-style-type: none"> <li>Other Additives:Yes incl animal src</li> </ul>	Requested by Taiwan



8	4.1.1	Added the following Tissue class names <ul style="list-style-type: none"> <li>• COMMON ILIAC ARTERY</li> <li>• FEMORAL ARTERY</li> <li>• VENA CAVA INFERIOR</li> </ul>	Requested by Austria
---	-------	--	----------------------

Version 4.12 June 2012			
	Section	Change	Rationale
1	2.3.2.2.4	Replaced “log” with “E” in exponential expressions.	Proposal 11-001
2	2.3.2.2.10	Replaced “log” with “E” in exponential expressions.	Proposal 11-001
3	3.3.2.2.3	Reworded definition of 6% HES + 5% DMSO.	To provide clarification on the reagents present by percent
4	3.3.2.2.3	Added NS HES + 5% DMSO	Requested by CTCLAG
5	4.1.3	Added new Skin Terminology: DERMIS; SKIN, FULL; SKIN, SPLIT	Requested by ETTAG and NATTAG
6	4.2.1	Added note about modifiers for Tissues	As part of an overall process to simplify coding, tissue Product Descriptions are being restructured to discontinue use of Modifiers.
7	4.3.2.1	<ul style="list-style-type: none"> <li>• Renamed Usage group to Processing Status</li> <li>• Added new attribute groups: Storage Solution, Meshed, Donor-Intended Recipient Relationship</li> </ul>	Requested by ETTAG and NATTAG
8	4.3.2.1	Updated Anatomical Position description	Consistency with Ocular terminology
9	4.3.2.2	Attribute Variable groups renumbered.	Section reorganized to match organization of Product Description Code Database.
10	4.3.2.2.1	Added Donor-Intended Recipient Relationship group	Requested by ETTAG and NATTAG
11	4.3.2.2.2	Added Meshed group	Requested by ETTAG and NATTAG



12	4.3.2.2.3	Added Storage Solution group	Requested by ETTAG and NATTAG
13	4.3.2.2.4	Added new terms to Type of Preservation group: Cryopreserved, Freeze dried, Glycerol (high conc), Refrigerated	Requested by ETTAG and NATTAG
14	4.3.2.2.5	Updated definitions in Processed to Reduce Cellular Components group by adding the word "intended"	ETTAG requested to acknowledge that sometimes cellular components may be reduced in processes that are not primarily performed for this purpose.
15	4.3.2.2.6	Added clarification to the definitions in the Anatomical Position group.	Consistency with Ocular terminology
16	4.3.3.2.7	Renamed Usage group to Processing Status group.	Requested by ETTAG and NATTAG
17	4.3.2.2.9	Added new terms to Pathogen Reduction group: Antibiotics, Combined process	Requested by ETTAG and NATTAG
18	4.3.2.2.9	<ul style="list-style-type: none"> <li>Updated definition of ETO to indicate the method of sterilization is validated</li> <li>Updated definition of Peracetic acid to indicate the method of sterilization is validated</li> </ul>	Requested by ETTAG.
19	5	Added new section for Ocular terminology	Requested by EBTAG
20	6	Renumbered Plasma Derivative section	Due to addition of Ocular terminology by EBTAG
21	7	Renumbered Retired Codes section	Due to addition of Ocular terminology by EBTAG
22	7.3	Retired Tissue terminology: <ul style="list-style-type: none"> <li>EYE, LEFT</li> <li>EYE, RIGHT</li> </ul>	New terminology developed for Ocular tissue.
23	7.3	Retired Tissue terminology from skin bounded list <ul style="list-style-type: none"> <li>SKIN</li> <li>SKIN, LARGE</li> <li>SKIN, SMALL</li> </ul>	New terminology developed for Skin tissue.



Version 4.11 May 2012			
	Section	Change	Rationale
1		No changes made to this document. Version numbering updated to correspond with current Product Description Code Database.	

Version 4.10 April 2012			
	Section	Change	Rationale
1	2.3.1.1	Added ACD-A-HES	Requested by The Netherlands
2	3.3.2.2.2	Added Filtered	Requested by The Netherlands
3	3.3.2.2.2	Added CD4 enriched	Requested by The Netherlands

Version 4.9 March 2012			
	Section	Change	Rationale
1	3.3.2.2.2	Added Alpha Beta T/B cell reduced	Requested by The Netherlands
2	4.1.2	Added: CORTICAL BONE, GROUND, PASTE CORTICAL BONE, GROUND, PUTTY	Requested by the UK
3	4.1.4	Added SKIN, FULL WITH HYPODERMIS	Requested by the UK
4	4.3.2.1	Renamed the Sterilization attribute group to Pathogen Reduction and updated its description to include decontamination of the product.	Requested by ETTAG
5	4.3.2.1	Added new attribute groups: <ul style="list-style-type: none"> <li>Processed to Reduce Cellular Components</li> <li>Type of Preservation</li> </ul>	Requested by ETTAG



6	4.3.2.2.2	<ul style="list-style-type: none"> <li>Renamed the Sterilization attribute group.</li> <li>Changed the attribute group default to “Not specified” and updated the definition.</li> <li>Renamed the Irradiated attribute to “Radiation sterilization” and updated the definition.</li> <li>Added attributes: No pathogen reduction, Pathogen reduced: Method NS.</li> </ul>	Requested by ETTAG
7	4.3.2.2.6	Added this new section for the new attribute group and variables.	Requested by ETTAG
8	4.3.2.2.7	Added this new section for the new attribute group and variables.	Requested by ETTAG

Version 4.8 February 2012			
	Section	Change	Rationale
1	3.1.2	Added this section on the Meaning of “TC”	To provide clarification on the intended use of TC products and specify the terminology is not meant to convey actual therapeutic benefits.
2	3.1.3	Reworded the definitions of TC products to emphasize that the product is intended for therapeutic use.	To provide clarification on the intended use of TC products.

Version 4.7 January 2012			
	Section	Change	Rationale
1	2.3.1.1	Added ACD-B>MAP	Inadvertent omission
2	2.3.1.1	Removed CP2DA and added it to section 6.1.2.1 for retired blood core conditions	Invalid anticoagulant
3	2.3.1.1	Added ACD-A>SAGM	Requested by Canada
4	3.1.1	Added PANCREATIC ISLET RINSE SOLUTION	Requested by Scotland





5	Appendix A	Removed the explanation on the way PAS terminology is reflected in the ISBT 128 Product Description Code Database	This explanation served to help transition into the new terminology. The Generic PAS nomenclature has been fully adopted.
6	Throughout document	Added a “Common Name” column to the various tables.	To help users relate the sometimes abbreviated terms used in the ISBT 128 Product Description Code Database with a more familiar term.



# ISBT 128 Standard Terminology for Blood, Cellular Therapy, and Tissue Product Descriptions

## Version Control Sheet 2011

Version 4.6 December 2011			
	Section	Change	Rationale
1	2.3.2.2.12	Added Hematocrit 0.7-0.8	Requested by Canada
2	3.1.1	Added NC, TUMOR CELLS	Requested by the US
3	3.1.1	Added TC, PANCREATIC ISLETS	Requested by Scotland
4	3.1.1	Rearranged the order of class names by Category 1 and Category 2 product types	Improve organization
5	4.1.2	Added the following class names: TENDON, QUADRICEPS, WITH BONE BLOCK TENDON, GRACILIS LIGAMENT, MEDIAL COLLATERAL, WITH BONE BLOCKS MENISCUS, MEDIAL, WITH TIBIA PLATEAU MENISCUS, LATERAL, WITH TIBIA PLATEAU LIGAMENT, ANTERIOR CRUCIATE, WITH BONE BLOCKS LIGAMENT, POSTERIOR CRUCIATE, WITH BONE BLOCKS TENDON, BICEPS FEMORIS, WITH BONE BLOCK TENDON, TIBIALIS ANTERIOR, WITH BONE BLOCK TENDON, TIBIALIS POSTERIOR, WITH BONE BLOCK TENDON, FLEXOR HALLUCIS LONGUS TENDON, FLEXOR DIGITORUM LONGUS TENDON, PERONEUS LONGUS WITH BONE BLOCK TENDON, ILIOTIBIALIS	Requested by Denmark



Version 4.5 November 2011			
	Section	Change	Rationale
1	2.3.2.2.5	Added Supernat rem/Albumin added	Requested by Canada
2	5	Changed the title of the section to Plasma Derivatives and added an introduction.	Clarification

Version 4.4 October 2011			
	Section	Change	Rationale
1	4.1.2	Added TENDON, PATELLA, WHOLE, WITH EXTENSOR	Requested by the UK

Version 4.3 September 2011			
	Section	Change	Rationale
1	4.1.2	Added FEMORAL HEAD, QUARTER	Requested by Canada
2	4.3.2.2.3	Updated definition of Pack	Added clarification to differentiate the definition of Pack from the new attributes added to the Unit of Issue group.
3	4.3.2.2.3	Added attributes Pack2 and Pack4	Requested by Canada
4	Appendix	Updated Reference	Corrected citation

Version 4.2 August 2011			
	Section	Change	Rationale
1	Standards Committee	Added John Armitage and Leigh Sims-Poston. Removed Deirdre Fehily.	Updated to reflect current status



		Updated credentials for Diane Wilson	
2	Warranty / Liability	Added a paragraph further describing role and responsibilities.	Clarification
3	4.1, 4.1.1, 4.1.2, 4.1.3, 4.1.4, 4.1.5	Reorganized the table of tissue classes and separated the classes into 5 broad categories in their own section: Cardio/Vascular, Musculo/Skeletal, Ocular, Skin, Other	Helpful in locating a particular class name
4	4.1.2	Added MENISCUS LATERAL and MENISCUS MEDIAL	Requested by Canada

Version 4.1 July 2011			
	Section	Change	Rationale
1		No changes made to this document. Version numbering updated to correspond with current Product Description Code Database.	

Version 4.0 June 2011			
	Section	Change	Rationale
1		No changes made.	No changes made.

Version 4.0 May 2011			
	Section	Change	Rationale
1		No changes made.	No changes made.

Version 4.0 April 2011			
	Section	Change	Rationale
1		No changes made.	No changes made.



Version 4.0 March 2011			
	Section	Change	Rationale
1		No changes made.	Version number updated for consistency with the Product Description Code Database version

Version 3.46 February 2011			
	Section	Change	Rationale
1	2.2.1	Added Lyophilized modifier	Requested by the US
2	2.2.1	Added Reconstituted modifier	Requested by the US
3	3.1.1	Added TC-MSC MD class	Requested by the US



**ISBT 128 Standard**  
**Standard Terminology for Blood, Cellular Therapy, and Tissue Product**  
**Descriptions (previously called Product Coding: Bounded Lists and Definitions)**

**Version Control Sheet**

	Section	Change	Rationale
<b>Version 3.45 December 2010</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.44 November 2010</b>			
1	2.2.1	Added "Washed Thawed" and "Washed Thawed Apheresis" modifiers	Requested by Poland
2	4.1.1	Added a "TIBIA SHAFT" tissue class	Requested by Canada
<b>Version 3.43 October 2010</b>			
1	2.3.1	Added PAS-F	Requested by vendor
<b>Version 3.42 September 3, 2010</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.41 September 1, 2010</b>			
1	4.1.1	Added the following class names: TENDON, TIBIALIS, ANTERIOR; TENDON, TIBIALIS, POSTERIOR; TIBIA; HUMERUS; HUMERUS DISTAL; HUMERUS PROXIMAL; TENDON PLANTARIS; ANKLE; RIB; FIBULA; HAMSTRING; CORTICOCANCELLOUS BONE, CRUSHED; CORTICOCANCELLOUS BONE, GROUND; SAPHENOUS VEIN	Requested by Canada
2	4.3.2.1	Added an attribute group for	Better managed as an



		Anatomical Position	attribute
3	4.3.2.2.5	Added Anatomical Position attribute group variables	Better managed as an attribute
<b>Version 3.40 August 2010</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.39 July 2010</b>			
1	2.3.1.1	Added descriptions in the table of volumes	Clarity
<b>Version 3.38 June 2010</b>			
1	3.1.1	Added NC, ADIPOSE CELLS	Requested by CTCLAG
2	3.1.1	Added NC, MENSTRUAL BLOOD	Requested by CTCLAG
<b>Version 3.37 May 2010</b>			
1	2.1.1	Removed LYMPHOCYTES and MONOCYTES from the Class table	Retired these terms for the labeling of blood products. These products will be classified as cellular therapy products.
2	4.1	Added a "TISSUE" class	Requested by NATTAG
3	6.1.1	Added LYMPHOCYTES and MONOCYTES to the retired blood Class table	Retired these terms for the labeling of blood products. These products will be classified as cellular therapy products.
<b>Version 3.36 April 2010</b>			
1	4.3.2.1	Rearranged the group names so they are listed in the same order as they appear in the Attribute table of the Product Code Database.	Consistency
2	5.2.1	Added a "Thawed" modifier	Requested by Sweden
3	5.3.1.1	Added a "refg" storage temperature	Requested by Sweden
<b>Version 3.35 March 2010</b>			
1	2.3.1	Added a table of the renamed platelet additive solutions with standard <i>ISBT 128</i> terminology and defined them based on their key ingredients.	PASs have non-standard terminology. Two solutions with basically the same ingredients may be called by different names by different companies. Therefore, <i>ISBT 128</i> defines platelet additive solutions in terms of their key



			ingredients.
2	2.3.1.1	Added extra examples to the unbounded list of volumes and temperatures.	To provide a better global representation.
3	2.3.2.2.12	Added new attribute of 0.4-0.5 to the Hematocrit attribute group.	Requested by Hong Kong
4	Appendix A	Relocated the table of platelet additive solutions.	Incorporated this information into section 2.3.1
<b>Version 3.34 February 2010</b>			
1	3.3.2.2.3	Added NS DMSO cryoprotectant attribute	Requested by Canada
2	3.3.2.2.3	Revised definitions to describe DMSO concentration of the actual product, not just the frozen product	Clarity
<b>Version 3.33 January 2010</b>			
1	3.2.1	Added Pooled, Single Donor Thawed Washed	Requested by the US
<b>Version 3.32 December 2009</b>			
1	2.3.1	Added a note in reference to Appendix A	To provide explanation to new PAS naming convention
2	2.3.1.1	Defined PASIIIMgK in terms of its ingredients.	To provide greater clarity
3	2.3.1.1	Added PAS-E.	Requested by Belgium.
4	2.3.1.1	Changed wording of definitions from, "The Plasma was frozen within..." to "The Plasma was placed in the freezer within..."	To give greater flexibility for different practices worldwide.
5	Appendix A	Added Appendix A to the end of the document.	To provide explanation to new PAS naming convention
<b>Version 3.31 October 2009</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.30 September 2009</b>			
1	Throughout document	Alphabetized lists of classes, modifiers, and attributes	Ease in search
2	2.3.2.1	Removed the Platelet Count Attribute Group	Attribute group retired
3	6.1.2.3	Added Platelet Count Attribute Group	Attribute group retired
4	2.3.2.2.1	Revised definition for "Not for tx or mnf" attribute	Clarification





<b>Version 3.29 August 2009</b>			
1	3.2.1	Added new modifier combination and definition for Cryopreserved Non-Mobilized	Requested by Sweden. Inadvertent omission in the February 2009 version control.
2	3.2.1	Added new modifier combination and definition for Thawed Washed Non-Mobilized	Requested by Sweden. Inadvertent omission in the February 2009 version control.
<b>Version 3.28 July 2009</b>			
1	2.3.1.1	Removed reference to Composol for PASIIIMgK	Inappropriate use of commercial name
<b>Version 3.27 June 2009</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.26 May 2009</b>			
1	2.3.1.1	Added new anticoagulant of CPD-50>SAGM.	Requested by Canada
<b>Version 3.25 April 2009</b>			
1	3.3.2.2.3	Added new attribute of 7.5% DMSO.	Requested by the US. This attribute was added to the database as part of version 3.18 in September 2008 but was inadvertently omitted from the Standard Terminology document.
<b>Version 3.24 March 2009</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.23 February 2009</b>			
1	3.3.2.2.3	Removed "DMSO reduced" from the Cryoprotectant attribute group	The Thawed Washed modifier includes DMSO reduction. The two terms describe the same process.
2	6.2.3.3.6	Added a retired table for the Cryoprotectant attribute group with the "DMSO reduced" attribute	Retired cellular therapy attribute
<b>Version 3.22 January 2009</b>			
1	3.1.1	Revised the definition for TC-	This name should not be used



		INV	for a product that is part of a blinded comparison study.
2	3.1.1	Added new Class and definition for TC-BLINDED STUDY	Requested by CTCLAG
<b>Version 3.21 December 2008</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.20 November 2008</b>			
1	3.1.1	Changed the Class name from TC-Tumor Derived to TC, Tumor Derived	TC, Tumor may be a collected product. A hyphen always indicates a final product, but a comma may either be a collection product or a final product.
2	3.1.1	Added new Class and definition for TC-TIL	Requested by CTCLAG
3	3.3.2.2.1	Revised the definitions for the Intended Use Group attribute variables	Clarity; products collected as "not for administration" may be further processed into non-transfusable products.
<b>Version 3.19 October 2008</b>			
1	3.3.2.2.2	Added Monocytes enriched	Requested by Austria
<b>Version 3.18 September 2008</b>			
1	Pg. 2	Added copyright message	
2	2.3.1	Omitted the text explanation for NS, None, and XX as part of the core conditions definitions	Duplication with the core conditions table
3	2.3.1.1	Revised definition of "XX" in the core conditions volume table	Clarity
4	2.3.1.1	Revised the definitions for "rt" and "20 – 24 C" in the core conditions temperature table	Clarity
5	2.3.1.1	Revised the definition for "None" in the core conditions anticoagulant table	Clarity
6	6.1.2.1	Retired the use of None/NS/<=-18C, None/NS/rt, and DMSO/NS/<-80C core conditions	Discontinued the use of "NS" to specify blood collection volume. The revised definition of XX will allow it to be used in place of "NS".



<b>Version 3.17 August 2008</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.16 July 2008</b>			
1	2.3.1.1	Added CPD>AS3	At the request of the US
2	2.3.1.1	Added CPD>SAGM	At the request of Canada. Previous codes for SAGM do not include the anticoagulant, which is required in Canada
<b>Version 3.15 June 2008</b>			
1	3.1.2	Added standardized abbreviations	These terms are commonly abbreviated in documents and standardization is desirable.
2	6.2.3.1	Deleted alb, HES, NaCitrate, Plasma and SSPP from Core Conditions retired codes	These terms only appeared in conjunction with other terms. The combinations are already on the list.
3	6.2.3.3.2	Indicated 6% HES + 5% DMSO and 10% DMSO have been moved to the Cryoprotectant group.	Clarity
4	6.2.3.3.4	Added From Buffy Coat, Density Enriched, and CD56 enriched	Inadvertently omitted.
<b>Version 3.14 May 2008</b>			
Title	Title	Title of document has been changed to Standard Terminology for Blood, Cellular Therapy, and Tissue Product Descriptions	To better describe the purpose of the document.
1	1	Changed title of chapter	To better describe the introductory nature of chapter
2	1	Reworded chapter	To better describe how product descriptions are created within the ISBT 128 Standard
3		Deleted information indicating that some terms found in the database do not appear in this in this document	These terms now appear in the chapter on retired codes
4	2.3.2.2.5	Added Complement inactivated	At the request of Sweden
5	2.3.2.2.7	Added Frozen <=26h	At the request of Austria



6	3.1	Explained the categories of Cellular Therapy classes	Improve clarity
7	6.2.1	Deleted TC, Whole Blood	Error correction. This code is not retired.
8	6.2.3.3.2	Deleted 6%HES + 5% DMSO and 10% DMSO	Error correction. These codes are not retired.
<b>Version 3.13 March 2008</b>			
1	2.1.1	Added POOLED FRESH FROZEN PLASMA as a product class	Per the request of Spain
2	3	Indicated information about "retired codes" could be found in Chapter 6 as well as in the Transition document	Retired code definitions are now included in this document
3	5	Added a chapter on retired codes.	A mechanism to retire codes (maintain them in the database for backwards compatibility but recommend against their use for new products) was established.
<b>Version 3.12 February 2008</b>			
1	1	Reworded	To add clarity and to include Derivatives
2	4.1.1	Added TENDON, PATELLA, WHOLE, SHAPED	Per request of the UK
3	5	Added Chapter 5, Derivatives	Per request of Finland
<b>Version 3.11, January 2008</b>			
1	2.3.2.2.11	Added Riboflavin-treated	Per request of US
<b>Version 3.10, December 2007</b>			
1	2.3.1.1	Added PASIIIMgK	Per request of Spain
<b>Version 3.9, November 2007</b>			
1	2.3.2.2.9	Added Quar:>=90d/retested	Per request of Spain
<b>Version 3.8, October 2007</b>			
1		No changes were made to this document. The numbering was updated to correspond with current Product Code Description database.	
<b>Version 3.7, August 2007</b>			
1	1	Indicated requests for new product codes should be submitted via an on-line request form. Indicated where instructions for product codes requests may be found, Explained why some codes	Clarified the process



		found in the database are not present in the Product Coding Bounded Lists and Definitions document.	
2	2.3.2.2.1	Reworded definition for “For mnf: non-injectable restr use	Clarity and consistency
3	2.3.2.2.1	Added attribute for “For mnf: injectable restr use	Request of the US
4	4.1.2	Redefined the following Class terms: <ul style="list-style-type: none"> <li>• Pericardial Patch</li> <li>• Aortic Arch</li> <li>• Aortic Patch</li> <li>• Cardiovascular Non-Valved Conduit</li> <li>• Meniscus</li> <li>• Meniscus, Left</li> <li>• Meniscus, Right</li> <li>• Tendon, Patella, Left</li> <li>• Tendon, Patella, Right</li> <li>• Tibia, Proximal, Left</li> <li>• Tibia, Proximal, Right</li> </ul>	More accurate definitions
5	4.1.2	Redefined the Modifier Cleaned Frozen	More accurate definition
6	4.1.2	Changed Class names (from →to) and re-alphabetized: <ul style="list-style-type: none"> <li>• Acellular Pericardial Patch → Pericardial Patch</li> <li>• Cancellous Bone Knee Slice → Cancellous Femoral Knee Slice</li> <li>• Cardiovascular Non-Valved Conduits → Aortic Non-Valved Conduit</li> <li>• Cortical Bone Ring → Cortical Femoral Bone Ring</li> <li>• Cortical Strip → Cortical Femoral Bone Strip</li> <li>• Cortico-Cancellous Bone Ring → Cortico-Cancellous Femoral Bone Ring</li> <li>• Cortico-Cancellous Bone Strip → Cortico-Cancellous Femoral Bone Strip</li> <li>• Whole Meniscus → Menisci</li> </ul>	More accurate descriptions <i>Note: Names which appear as label text may be nationally defined. Therefore, changes in names to the database do not have to affect the name printed on the label. However, consideration should be given to using the more accurate terms for products labeled in the future.</i>



		<ul style="list-style-type: none"> <li>• Meniscus, Whole, Left → Menisci, Left</li> <li>• Meniscus, Whole, Right → Menisci, Right</li> <li>• Tendon, Semitendinosus → Tendon, Semitendinosus</li> </ul>	
7	4.1.2	Deleted Pericarium Pool	While term will be retained in the database for backward compatibility, it should not be selected for new products
8	4.1.2	Added Tendon, Semitendinosus, Left and Tendon Semitendinosus, Right	Inadvertently omitted from this document.
9	4.1.2	Added class: Cancellous Tibial Knee Slice	Per request of Poland and the UK
10	4.2.1	Added modifier: Cleaned Frozen Acellular	Per request of Poland and the UK
11	4.3.2.2.2	Added definition for Paracetic Acid	Completeness
<b>Version 3.6, July 2007</b>			
1	3.2.2.4	Deleted "Not Specified" as the default value. Made "No third party component added" the default value.	The default value should be the most common condition. "Not specified" is not the most common condition.
2	3.2.2.5	Deleted "Not Specified" as the default value. Made "No additives other than as part of the anticoagulant solution at the time of collection" the default value.	The default value should be the most common condition. "Not specified" is not the most common condition.
3	3.2.2.6	Deleted "Not specified" as the default value. Made "Not genetically modified" the default value.	The default value should be the most common condition. "Not specified" is not the most common condition.
<b>Version 3.5, June 2007</b>			
1	3.1	Redefined class terms: <ul style="list-style-type: none"> <li>• HPC, APHERESIS</li> <li>• HPC, CORD</li> <li>• HPC, MARROW</li> <li>• HPC, WHOLE BLOOD</li> <li>• TC, APHERESIS</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.



		<ul style="list-style-type: none"> <li>• CONCURRENT PLASMA, APHERESIS</li> <li>• TC, APHERESIS</li> </ul>	
2	3.1	Changed HPC, CORD to HPC, CORD BLOOD	More precise term.
3	3.1	<p>Retired Class terms (these codes should not be assigned to NEW products but are maintained for backward compatibility):</p> <ul style="list-style-type: none"> <li>• T CELLS</li> <li>• T CELLS, APHERESIS</li> <li>• LYMPHOCYTES, APHERESIS</li> <li>• POOLED, HPC, APHERESIS</li> <li>• MNC, APHERESIS</li> <li>• TC-T</li> <li>• TC-CTL, APHERESIS</li> <li>• TC, WHOLE BLOOD</li> <li>• TC-T, WHOLE BLOOD</li> <li>• TC-CTL, WHOLE BLOOD</li> <li>• TC-DC, MARROW</li> <li>• TC-DC, CORD</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
4	3.1	<p>Added Class terms:</p> <ul style="list-style-type: none"> <li>• TC, MARROW</li> <li>• TC, WHOLE BLOOD</li> <li>• TC, CORD BLOOD</li> <li>• TC-T CELLS</li> <li>• TC-CTL</li> <li>• TC-T REG CELLS</li> <li>• TC-DC</li> <li>• TC-NK CELLS</li> <li>• TC-TUMOR DERIVED</li> <li>• TC-MSD</li> <li>• TC-APC</li> <li>• TC-INV</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG).
5	3.2.1	<p>Redefined Modifier terms:</p> <ul style="list-style-type: none"> <li>• Cryopreserved</li> <li>• Thawed</li> <li>• Heparinized</li> <li>• Washed</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
6	3.2.1	Retired modifiers term: Frozen	Was redundant with Cryopreserved
7	3.2.1	Added Modifier terms:	Per the Cellular Therapy



		<ul style="list-style-type: none"> <li>• Mobilized</li> <li>• Non-mobilized</li> <li>• Pooled, Single Donor</li> <li>• Thawed Washed</li> </ul>	Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
8	3.3.1.1	<p>Retired anticoagulants (these codes should not be assigned to NEW products but are maintained for backward compatibility):</p> <ul style="list-style-type: none"> <li>• ACD-A</li> <li>• ACD-A+10% DMSO</li> <li>• ACD-A+Heparin</li> <li>• ACD-A + Heparin+6% HES</li> <li>• ACD-A + Heparin+6% HES + 10% DMSO</li> <li>• Alb</li> <li>• CPD</li> <li>• CPD+Heparin</li> <li>• CPDA-1</li> <li>• CPDA-1 + DMSO</li> <li>• CPDA-1+10% DMSO+30% SSPP+10% plasma</li> <li>• CPDA-1+10% DMSO+0.8% HES+1% dextran</li> <li>• DMSO</li> <li>• HES</li> <li>• HES-DMSO</li> <li>• NaCitrate</li> <li>• PBS</li> <li>• PBS + alb + 4% NaCitrate</li> <li>• Plasma</li> <li>• SSPP</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
9	3.3.1.1	<p>Redefined anticoagulant terms:</p> <ul style="list-style-type: none"> <li>• Heparin</li> <li>• None</li> <li>• Not specified</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
10	3.3.1.1	<p>Added anticoagulants:</p> <ul style="list-style-type: none"> <li>• Citrate</li> <li>• Citrate and Heparin</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
11	3.3.1.1	Redefined storage	Per the Cellular Therapy





		temperatures: • rt	Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
12	3.3.1.1	Added Storage Temperature: • $\leq -150^{\circ}\text{C}$ • $\text{N}_2$	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
13	3.3.2.1	Retired Attribute groups (these codes should not be assigned to NEW products but are maintained for backward compatibility): • System Integrity • Preparation: Additional Information • Final Product: Additional Information • Further Processing	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
14	3.3.2.1	Redefined Attribute group term: • Manipulation	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
15	3.3.2.1	Added Attribute groups: • Preparation: Cryoprotectant • Preparation: Blood component from third party donor • Preparation: Additional additives • Genetically modified	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
16	3.3.3.1 (Version 3.5: 3.3.2.2.1)	Reworded variables in Intended Use group: • Changed “For Transfusion” to “For Administration” • Changed “Not for tx” to “Not for administration or further processing”	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
17	3.3.3.1 (Version 3.5: 3.3.2.2.1)	Added a variable to the Intended Use group: • For further processing	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product</i>



			<i>Coding Transition Document for rationale.</i>
18	3.3.3.2	Retired variables from the System Integrity Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility):	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
19	3.3.3.3	Retired variables from the Preparation: Additional Information Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility):	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
20	3.3.3.4	Retired variables from the Final Product: Additional Information Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility):	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
21	3.3.3.5 (Version 3.5: 3.3.2.2.2)	Retired variable terms from Manipulation Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility): <ul style="list-style-type: none"> <li>• Minimal</li> <li>• Extensive</li> <li>• CD8-depleted</li> <li>• CD34-removed</li> <li>• AC133-selected</li> <li>• From buffy coat</li> <li>• T-Cells depleted</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
22	3.3.3.5 (Version 3.5: 3.3.2.2.2)	Redefined variable terms from Manipulation Attribute group: <ul style="list-style-type: none"> <li>• CD34-enriched</li> <li>• PUV-treated</li> <li>• Buffy coat enriched</li> <li>• RBC-reduced</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
23	3.3.3.5 (Version 3.5: 3.3.2.2.2)	Added variables to the Manipulation Attribute group: <ul style="list-style-type: none"> <li>• Diluted</li> <li>• Plasma reduced</li> <li>• Mononuclear cells enriched</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.



		<ul style="list-style-type: none"> <li>• T-cell reduced</li> <li>• B-cell reduced</li> <li>• T/B-cell reduced</li> <li>• CD8 reduced</li> <li>• CD34 enriched</li> <li>• CD133 enriched Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.</li> <li>• Tumor cells reduced</li> <li>• Cultured</li> </ul>	
24	3.3.3.6	<p>Retired variable terms from Further Processing Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility)</p> <ul style="list-style-type: none"> <li>• Default: No further processing</li> <li>• Volume DMSO reduced</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
25	Version 3.5: 3.3.2.2.3	<p>Added variable terms to Cryoprotectant group:</p> <ul style="list-style-type: none"> <li>• 6% HES + 5% DMSO</li> <li>• 10% DMSO</li> <li>• 5% DMSO</li> <li>• DMSO reduced</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
26	Version 3.5: 3.3.2.2.4	<p>Added variable terms to Preparation: Blood component from third party donor group</p> <ul style="list-style-type: none"> <li>• Default: Not Specified</li> <li>• 3<sup>rd</sup> Party Component: No</li> <li>• 3<sup>rd</sup> party Component: Yes</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
27	Version 3.5: 3.3.2.2.5	<p>Added variable terms to Preparation: Other Additives group</p> <p>Default: Not specified</p> <p>Other additives: No</p> <p>Other additives: yes</p>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
28	Version 3.5: 3.3.2.2.6	<p>Added variable terms to Genetically Modified Group</p> <p>Default: Genetic modification not specified</p> <p>Genetically modified: No</p>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i>



		Genetically modified: Yes	for rationale.
<b>Version 3.4, May 2007</b>			
1	2.3.3.10	Added 10 donor pool to Dosage: Additional Information Group	Per request of the US
2	4.1	Added Calcar Femorale	Per request of Denmark
<b>Version 3.3, April 2007</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.2, March 2007</b>			
1	2.3.1.1	Added NaCitrate—HES—ACD-A	Per request of the US
<b>Version 3.1.x, February 2007</b>			
1	2.3.1	Updated reference in note to current edition of Mollison's Blood Transfusion in Clinical Medicine	Update
2	2.3.1.1	Added MAP as an additive; corrected spelling of "hydroxyl"	Per request of China; typographical error
3	2.3.3.14	Added definition of default for monitoring	Inadvertent omission
4	2.3.3.4	Added ResLeu:<2.5log6	Per request of China
5	2.3.3.6	Added 25 mL and 50 mL	Per request of China
6	2.3.3.7	corrected spelling of "hydroxyl"	Typographical error
7	3.3.1.1	Added definition for "XX"	Inadvertent omission
8	3.3.3.1	Corrected spelling of citrate	Typographical error
<b>Version 3.0, January 2007</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 2.18, December 2006</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 2.17, November 2006</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code	



		Description database.	
<b>Version 2.16, September 2006</b>			
	4.1	Revised or added definitions for Costal Cartilage, Osteochondral, bone and tendon.	
<b>Version 2.15, August 2006</b>			
	2.3.3.5	Added Plasma Reduced/Plasma added	Per request of the US
	2.3.3.6	Change MI to mL	Typographical error
<b>Version 2.14, July 2006</b>			
1	4.1	Added AORTIC PATCH	Per request of the UK
2	4.1	Added PULMONARY PATCH	Per request of the UK
3	4.1	Alphabetized classes	Ease of use
<b>Version 2.13, June 2006</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database	
<b>Version 2.12, April 2006</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database	